Life Sciences · NYSE: IQV
IQVIA earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 4 Feb 2027
Latest: Q3 2026
IQVIA's strongest clinical bookings since 2022, driven by full-service wins and AI-enabled bids, came as it deployed 415 AI agents and raised its full-year outlook.
IQVIA saw demand improve across both businesses. Clinical customers awarded more full-service work, including large pharma and emerging biopharma, and win rates rose by two to three points. In commercial, pipelines are at record levels and new drug launches are up. The company says AI is helping it win business: it has deployed 415 agents, launched IQVIA Explorer, and shortened one large trial program by nine months.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $4.0B * |
| Q1 2025 | $3.8B |
| Q2 2025 | $4.0B |
| Q3 2025 | $4.1B |
| Q4 2025 | $4.4B * |
| Q1 2026 | $4.2B |
| Q2 2026 | $4.4B |
| Q3 2026 | $4.4B |
Data
| Q1 2025 | $1.40 |
| Q2 2025 | $1.54 |
| Q3 2025 | $1.93 |
| Q1 2026 | $1.61 |
| Q2 2026 | $1.53 |
| Q3 2026 | $2.10 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 15.8% |
| Q1 2025 | 13.0% |
| Q2 2025 | 12.6% |
| Q3 2025 | 13.5% |
| Q4 2025 | 14.4% |
| Q1 2026 | 12.4% |
| Q2 2026 | 11.6% |
| Q3 2026 | 12.9% |
Data
| Q4 2024 | $721.0M |
| Q1 2025 | $426.0M |
| Q2 2025 | $292.0M |
| Q3 2025 | $772.0M |
| Q4 2025 | $561.0M |
| Q1 2026 | $491.0M |
| Q2 2026 | $360.0M |
| Q3 2026 | $667.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.0Bd | $3.8B | $4.0B | $4.1B | $4.4Bd | $4.2B | $4.4B | $4.4B |
| Operating income | $626.0Md | $496.0M | $506.0M | $553.0M | $627.0Md | $514.0M | $506.0M | $572.0M |
| Operating margin | 15.8% | 13.0% | 12.6% | 13.5% | 14.4% | 12.4% | 11.6% | 12.9% |
| Net income | $437.0Md | $249.0M | $266.0M | $331.0M | $514.0Md | $274.0M | $256.0M | $350.0M |
| Diluted EPS | — | $1.40 | $1.54 | $1.93 | — | $1.61 | $1.53 | $2.10 |
| Operating cash flow | $885.0Md | $568.0M | $443.0Md | $908.0Md | $735.0Md | $618.0M | $558.0Md | $825.0Md |
| Capital expenditure | $164.0Md | $142.0M | $151.0Md | $136.0Md | $174.0Md | $127.0M | $198.0Md | $158.0Md |
| Free cash flow | $721.0M | $426.0M | $292.0M | $772.0M | $561.0M | $491.0M | $360.0M | $667.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 27 Oct 202610-Q for the period ended 30 Sep 2026SEC ↗
- 28 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 5 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 17 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 28 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 22 Jul 202510-Q for the period ended 30 Jun 2025SEC ↗
- 6 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 13 Feb 202510-K for the period ended 31 Dec 2024SEC ↗